Quest Diagnostics Incorporated (LON:0KSX)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 15.59B +5.8% |
| Revenue (ttm) | 8.54B +11.0% |
| Net Income | 772.45M +14.2% |
| EPS | 6.85 +14.4% |
| Shares Out | n/a |
| PE Ratio | 20.18 |
| Forward PE | 17.06 |
| Dividend | 2.43 (1.28%) |
| Ex-Dividend Date | Apr 6, 2026 |
| Volume | 50 |
| Average Volume | 417 |
| Open | 187.15 |
| Previous Close | 191.23 |
| Day's Range | 187.15 - 189.09 |
| 52-Week Range | 165.35 - 214.44 |
| Beta | 0.60 |
| RSI | 47.49 |
| Earnings Date | Apr 21, 2026 |
About Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceu... [Read more]
Financial Performance
In 2025, Quest Diagnostics's revenue was $11.04 billion, an increase of 11.78% compared to the previous year's $9.87 billion. Earnings were $988.00 million, an increase of 14.09%.
Financial numbers in USD Financial StatementsNews
Quest Diagnostics Prices $500 Million of Senior Notes
SECAUCUS, N.J., April 27, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering...
Quest Diagnostics price target raised to $225 from $220 at Truist
Truist raised the firm’s price target on Quest Diagnostics (DGX) to $225 from $220 and keeps a Hold rating on the shares after its Q1 earnings beat. Core trends were…
Quest Diagnostics price target raised to $220 from $210 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Quest Diagnostics (DGX) to $220 from $210 and keeps a Neutral rating on the shares.
Quest Diagnostics price target raised to $229 from $224 at Baird
Baird raised the firm’s price target on Quest Diagnostics (DGX) to $229 from $224 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
Quest Diagnostics price target raised to $245 from $225 at BofA
BofA raised the firm’s price target on Quest Diagnostics (DGX) to $245 from $225 and keeps a Buy rating on the shares after Q1 results came in well ahead of…
Quest Diagnostics price target raised to $230 from $225 at Barclays
Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $230 from $225 and keeps an Overweight rating on the shares. The company’s “solid beat/raise” quarter underscores the momentum…
Quest Diagnostics price target raised to $225 from $210 at Evercore ISI
Evercore ISI raised the firm’s price target on Quest Diagnostics (DGX) to $225 from $210 and keeps an In Line rating on the shares after the company reported a “solid”…
Quest Diagnostics price target raised to $225 from $220 at Jefferies
Jefferies raised the firm’s price target on Quest Diagnostics (DGX) to $225 from $220 and keeps a Buy rating on the shares following a beat on sales and EPS, led…
Early notable gainers among liquid option names on April 21st
Notable gainers among liquid option names this morning include UnitedHealth (UNH) $353.95 +30.47, D R Horton (DHI) $165.64 +12.30, Quest Diagnostics (DGX) $209.50 +13.19, Steel Dynamics (STLD) $222.80...
Quest Diagnostics Earnings Call Transcript: Q1 2026
Q1 2026 saw over 9% revenue growth and a 13% rise in adjusted EPS, driven by strong organic demand, advanced diagnostics, and productivity gains from AI and automation. Full-year guidance for revenue and EPS was raised, with continued investment in innovation and digital transformation.
Quest Diagnostics raises full-year forecast, posts strong quarter on testing demand
Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient demand for routine diagnostic testing.
Quest Diagnostics raises FY26 adjusted EPS view to $10.63-$10.83
Previous view $10.50-$10.70. Consensus $10.63. Raises revenue view to $11.78B-$11.9B from $11.7B-$11.82B, consensus $11.76B.
Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted dilute...
City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers
Fourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancer SECAUCUS, N.J. and LOS ANGELES...
Quest Diagnostics target cut, added to ‘Tactical Outperform’ list at Evercore
Evercore ISI lowered the firm’s price target on Quest Diagnostics (DGX) to $210 from $220 and keeps an In Line rating on the shares as the firm made several price…
Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026
SECAUCUS, N.J., March 19, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report first quarter 2026 financial...
Quest Diagnostics elects Timothy Wentworth to Board of Directors
Quest Diagnostics (DGX) has elected Timothy Wentworth to serve as a director. Including Wentworth, the company’s board has eleven members. Wentworth was most recently CEO of Walgreens Boots Alliance. ...
Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors
SECAUCUS, N.J., March 12, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced that its board of directors has electe...
Quest Diagnostics Transcript: Leerink Global Healthcare Conference 2026
Expanded national coverage and specialty test innovation drove strong volume and share gains, with major partnerships like Corewell adding significant revenue. AI and automation are advancing lab operations and patient engagement, while Project Nova's rollout is on track for 2027 benefits.
Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results
New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data to help explain results and uncover potential health risks SECAUCUS, N.J., March 2, 2026 /PRNewswire/ -- ...
Digi Power X Graduates to Cboe Canada
TORONTO--(BUSINESS WIRE)---- $DGX #Cboe--Digi Power X Inc. has graduated from the venture markets and is now listed under the symbol DGX on Cboe Canada,.
Quest Diagnostics names Benjamin Beauvalot VP, Chief Strategy and M&A Officer
Quest Diagnostics (DGX) announced that Benjamin Beauvalot has joined the company as SVP, Chief Strategy and M&A Officer. Prior to joining Quest, Beauvalot held leadership positions in strategy and M&A...
Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer
Veteran M&A and transformation leader from Danaher and Patheon joins the Quest Diagnostics executive team SECAUCUS, N.J., Feb. 26, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provide...
Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference
SECAUCUS, N.J., Feb. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financ...
Quest Diagnostics price target raised to $235 from $210 at Mizuho
Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $235 from $210 and keeps an Outperform rating on the shares.